A mitochondrial-targeted nanomedicine based on hollow mesoporous silica nanoparticles for enhanced colorectal cancer therapy

IF 4.7 3区材料科学 Q2 CHEMISTRY, PHYSICAL

Colloid and Interface Science Communications Pub Date : 2025-03-25 DOI:10.1016/j.colcom.2025.100833

Jin Liu , Tianle Liu , Chi Zhang , Ziyou Wang , Xinyi Zhang , Chuanchuan Hao , Dan Wang , Guohui Cheng

{"title":"A mitochondrial-targeted nanomedicine based on hollow mesoporous silica nanoparticles for enhanced colorectal cancer therapy","authors":"Jin Liu , Tianle Liu , Chi Zhang , Ziyou Wang , Xinyi Zhang , Chuanchuan Hao , Dan Wang , Guohui Cheng","doi":"10.1016/j.colcom.2025.100833","DOIUrl":null,"url":null,"abstract":"<div><div>By focusing on mitochondria as a therapeutic target, strategies can be devised to deplete ATP levels, thereby potentially circumventing the emergence of MDR. In this study, we developed a surface-modified hyaluronic acid (HA), mitochondrial targeted hollow mesoporous silicon nanomedicine (PB@HMSN-HA) co-loaded with berberine (BBR) and paclitaxel (PTX) for enhanced colorectal cancer therapy. The modified HA can selectively bind to tumor cells that overexpress the CD44 receptor, leading to the accumulation of PB@HMSN-HA at the tumor site and improving tumor targeting efficiency. After cellular internalization, the liberated positively charged BBR, which is specifically targeted to mitochondria, induces a reduction in ATP levels. Depletion of ATP subsequently results in a reduction of drug efflux, thereby amplifying the antitumor efficacy of PTX. Therefore, this combination therapy strategy targeting mitochondria serves as an important reference for clinical oncological chemotherapy.</div></div>","PeriodicalId":10483,"journal":{"name":"Colloid and Interface Science Communications","volume":"66 ","pages":"Article 100833"},"PeriodicalIF":4.7000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colloid and Interface Science Communications","FirstCategoryId":"88","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2215038225000172","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

Abstract

By focusing on mitochondria as a therapeutic target, strategies can be devised to deplete ATP levels, thereby potentially circumventing the emergence of MDR. In this study, we developed a surface-modified hyaluronic acid (HA), mitochondrial targeted hollow mesoporous silicon nanomedicine (PB@HMSN-HA) co-loaded with berberine (BBR) and paclitaxel (PTX) for enhanced colorectal cancer therapy. The modified HA can selectively bind to tumor cells that overexpress the CD44 receptor, leading to the accumulation of PB@HMSN-HA at the tumor site and improving tumor targeting efficiency. After cellular internalization, the liberated positively charged BBR, which is specifically targeted to mitochondria, induces a reduction in ATP levels. Depletion of ATP subsequently results in a reduction of drug efflux, thereby amplifying the antitumor efficacy of PTX. Therefore, this combination therapy strategy targeting mitochondria serves as an important reference for clinical oncological chemotherapy.

Abstract Image

查看原文本刊更多论文

一种基于中空介孔二氧化硅纳米颗粒的线粒体靶向纳米药物，用于增强结直肠癌治疗

通过将线粒体作为治疗靶点，可以设计出降低ATP水平的策略，从而潜在地避免耐多药的出现。在这项研究中，我们开发了一种表面修饰透明质酸（HA），线粒体靶向中空介孔硅纳米药物（PB@HMSN-HA），共载小檗碱（BBR）和紫杉醇（PTX），用于增强结直肠癌治疗。修饰后的HA可选择性结合过表达CD44受体的肿瘤细胞，使PB@HMSN-HA在肿瘤部位积累，提高肿瘤靶向效率。在细胞内化后，释放的带正电的BBR，专门针对线粒体，诱导ATP水平的降低。ATP的耗竭随后导致药物外排减少，从而增强PTX的抗肿瘤功效。因此，这种针对线粒体的联合治疗策略可作为临床肿瘤化疗的重要参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Colloid and Interface Science Communications Materials Science-Materials Chemistry

CiteScore

9.40

自引率

6.70%

发文量

125

审稿时长

43 days

期刊介绍： Colloid and Interface Science Communications provides a forum for the highest visibility and rapid publication of short initial reports on new fundamental concepts, research findings, and topical applications at the forefront of the increasingly interdisciplinary area of colloid and interface science.